323 related articles for article (PubMed ID: 24743519)
1. Rates of febrile neutropenia with pegfilgrastim on same day versus next day of CHOP with or without rituximab.
Cheng C; Gallagher EM; Yeh JY; Earl MA
Anticancer Drugs; 2014 Sep; 25(8):964-9. PubMed ID: 24743519
[TBL] [Abstract][Full Text] [Related]
2. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
3. Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapy.
McBride A; Alrawashdh N; Bartels T; Moore L; Persky D; Abraham I
Future Oncol; 2021 Sep; 17(26):3485-3497. PubMed ID: 34241542
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of relative dose intensity in patients with non-Hodgkin lymphoma receiving CHOP-based chemotherapy and pegfilgrastim.
Balducci L; Mo M; Abella E; Saven A
Am J Clin Oncol; 2014 Dec; 37(6):603-10. PubMed ID: 25350463
[TBL] [Abstract][Full Text] [Related]
5. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
Shin HJ; Chung JS; Song MK; Kim SK; Choe S; Cho GJ
Cancer Chemother Pharmacol; 2012 May; 69(5):1165-72. PubMed ID: 22215473
[TBL] [Abstract][Full Text] [Related]
6. Primary prophylaxis with pegfilgrastim during the first cycle of R-CHOP to avoid reduction of dose intensity in elderly patients.
Ise M; Matsuda K; Shimura A; Masamoto Y; Kurokawa M
Int J Hematol; 2021 Jun; 113(6):823-831. PubMed ID: 33738702
[TBL] [Abstract][Full Text] [Related]
7. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Jin UR; Park JS
J Korean Med Sci; 2014 Nov; 29(11):1493-500. PubMed ID: 25408580
[TBL] [Abstract][Full Text] [Related]
8. Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma.
Langeberg WJ; Siozon CC; Page JH; Morrow PK; Chia VM
Support Care Cancer; 2014 Aug; 22(8):2167-75. PubMed ID: 24652049
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2).
Yokoyama M; Kusano Y; Nishihara A; Inoue N; Nishimura N; Mishima Y; Terui Y; Nukada T; Nomura T; Hatake K
Support Care Cancer; 2020 Feb; 28(2):571-579. PubMed ID: 31093770
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.
Kang KW; Lee BH; Jeon MJ; Yu ES; Kim DS; Lee SR; Sung HJ; Choi CW; Park Y; Kim BS
Cancer Med; 2020 Sep; 9(17):6102-6110. PubMed ID: 32633471
[TBL] [Abstract][Full Text] [Related]
11. G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.
Vitolo U; Angrili F; DeCosta L; Wetten S; Federico M
Med Oncol; 2016 Dec; 33(12):139. PubMed ID: 27822615
[TBL] [Abstract][Full Text] [Related]
12. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
Lyman GH; Delgado DJ
Cancer; 2003 Dec; 98(11):2402-9. PubMed ID: 14635075
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
Lyman G; Lalla A; Barron R; Dubois RW
Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
[TBL] [Abstract][Full Text] [Related]
14. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
[TBL] [Abstract][Full Text] [Related]
15. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
Grigg A; Solal-Celigny P; Hoskin P; Taylor K; McMillan A; Forstpointner R; Bacon P; Renwick J; Hiddemann W;
Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group.
Smith GM; Child JA; Cullen MH; Bailey NP; Woodruffe CM; Fletcher J; Earl H; Barnard D
Hematol Oncol; 1996 Dec; 14(4):193-201. PubMed ID: 9267465
[TBL] [Abstract][Full Text] [Related]
18. [Clinical effect of recombinant human G-CSF on neutropenia induced by chemotherapy for non-Hodgkin's lymphoma].
Oyama A; Ota K; Asano S; Takaku F; Miyazaki T; Uzuka Y; Omine M; Furusawa S; Hirashima K; Sanpi K
Nihon Gan Chiryo Gakkai Shi; 1990 Aug; 25(8):1619-34. PubMed ID: 1700040
[TBL] [Abstract][Full Text] [Related]
19. Frequency and severity of neutropenia in diffuse large B-cell non Hodgkin's lymphoma after first cycle of chemotherapy comprising cyclophosphamide, doxorubicin, vincristine with prednisolone.
Nadeem M; Idrees M; Khattak J; Hussain I; Amin Z; Arif S; Zeeshan M; Hussain M
J Ayub Med Coll Abbottabad; 2011; 23(1):80-3. PubMed ID: 22830154
[TBL] [Abstract][Full Text] [Related]
20. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.
Hill G; Barron R; Fust K; Skornicki ME; Taylor DC; Weinstein MC; Lyman GH
J Med Econ; 2014 Jan; 17(1):32-42. PubMed ID: 24028444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
